Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Equity Bottom-Up

<p>A key uncertainty for Nexstim was removed in December as the FDA confirmed that only one additional stroke rehabilitation trial in 60 patients will be required to seek de novo 510(k) regulatory approval for the NBT system. US approval might be obtained during Q418. Nexstim has used &#8364;8.8m from the Bracknor/Sitra funding arrangement and had &#8364;8.2m in cash in December. A further &#8364;3.2m can be raised from the arrangement. Excluding 30m issued warrants, this could fund Nexstim until late 2018. The NBS system achieved &#8364;2.5m in sales in 2016, with modest increases anticipated by Nexstim for 2017; new US distributors have been appointed.</p>

A key uncertainty for Nexstim was removed in December as the FDA confirmed that only one additional stroke rehabilitation trial in 60 patients will be required to seek de novo 510(k) regulatory approval for the NBT system. US approval might be obtained during Q418. Nexstim has used &#8364;8.8m from the Bracknor/Sitra funding arrangement and had &#8364;8.2m in cash in December. A further &#8364;3.2m can be raised from the arrangement. Excluding 30m issued warrants, this could fund Nexstim until late 2018. The NBS system achieved &#8364;2.5m in sales in 2016, with modest increases anticipated by Nexstim for 2017; new US distributors have been appointed.

Finland

Nexstim Oyj manufactures, markets, and develops medical equipment. The Company  offers brain stimulation devices and navigation systems for brain research.  Nexstim offers its products and services to hospitals and brain research  centers throughout the world.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Nexstim Oyj (NXTMH FH)

Funded and back on stroke trial track

A key uncertainty for Nexstim was removed in December as the FDA confirmed that only one additional stroke rehabilitation trial in 60 patients will...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)